Skip to main content
. Author manuscript; available in PMC: 2017 Jul 30.
Published in final edited form as: J Alzheimers Dis. 2017;56(1):229–237. doi: 10.3233/JAD-160562

Figure 1.

Figure 1

Effect of BChE-K genotype on cognitive decline in control (A and C) vs. donepezil treated (B and D) individuals at the end of the 36-months trial. Box plot of the mean changes of MMSE (A and B) and CDR-SB (C and D) by genotype and by treatment groups. A significant association is found between BChE K–genotype and response to donepezil (B and D).